These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32608356)

  • 1. [Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad].
    Petursdottir A; Gunnarsson O; Valsdottir EB
    Laeknabladid; 2020 Jul; 106(7):344-348. PubMed ID: 32608356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
    Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
    Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
    Rao A; Mui J; Barat S; Matar AA; Alzahrani N; Morris DL
    Anticancer Res; 2021 Nov; 41(11):5569-5575. PubMed ID: 34732427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.
    Ward EP; Okamuro L; Khan S; Hosseini M; Valasek MA; Ronquillo N; Kelly KJ; Veerapong J; Lowy AM; Baumgartner J
    Hum Pathol; 2021 Jul; 113():104-110. PubMed ID: 33905776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience.
    Gupta N; Asif S; Gandhi J; Rajpurohit S; Singh S
    Indian J Gastroenterol; 2017 Mar; 36(2):126-130. PubMed ID: 28393331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
    Schneider MA; Eshmuminov D; Lehmann K
    Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Ahmed S; Levine EA; Randle RW; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2014 Dec; 21(13):4226-31. PubMed ID: 25034815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis.
    Bekhor E; Carr J; Hofstedt M; Sullivan B; Solomon D; Leigh N; Bolton N; Golas B; Sarpel U; Labow D; Magge D
    Ann Surg Oncol; 2020 May; 27(5):1448-1455. PubMed ID: 31873928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors.
    Votanopoulos KI; Swords DS; Swett KR; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2013 Nov; 20(12):3899-904. PubMed ID: 23800899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.